May 16, 2022
|
May 23, 2022
|
April 22, 2024
|
August 31, 2022
|
December 2025 (Final data collection date for primary outcome measure)
|
- RP2D [ Time Frame: 1 year ]
Based on the observed number of dose-limiting toxicities (DLTs) during the first cycle. Dose-limiting toxicity is based on the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Dose-limiting toxicities will be evaluated during the first cycle (28 days) of treatment in up to 3 cohorts during Phase 1b. A DLT will be defined as any of the toxicities listed in the protocol that are not clearly due to breast cancer or extraneous causes.
- Objective Response Rate [ Time Frame: 3 years ]
Defined as the proportion of patients with a best overall response of either a complete response or partial response per blinded independent central review, per RECIST version 1.1.
|
- The number of patients in the Phase 1b part of the study with any adverse events (AE). [ Time Frame: 1 year ]
To determine the safety and tolerability of the abemaciclib and elacestrant combination the number of patients with adverse events (AE) that occur on or after C1D1 of therapy, AE severities will be classified using the CTCAE v5.0.
- Assess the efficacy of the drug combination of abemaciclib and elacestrant in the Phase 2 part of the study [ Time Frame: 3 years ]
Determine the objective response rate (ORR; the proportion of patients with a best overall response of either a complete response or partial response) per blinded independent central review
|
|
- Intracranial Response Rate per Response Evaluation Criteria in Solid Tumors (RECIST) [ Time Frame: 3 years ]
Defined as the proportion of patients achieving a best overall response of confirmed partial response + complete response, based on intracranial lesions per RECIST version 1.1 and blinded independent central review.
- Intracranial Response Rate per Response Assessment in Neuro-Oncology (RANO) [ Time Frame: 3 years ]
Defined as the proportion of patients achieving a best overall response of confirmed partial response plus complete response, based on intracranial lesions (per RANO criteria) and per blinded independent central review.
- Duration of Tumor Response [ Time Frame: 3 years ]
Defined as the duration of time from the date when criteria are met for either a complete response or partial response, per RECIST v1.1, until the first date that progressive disease is objectively documented, per blinded independent central review.
- Clinical Benefit Rate [ Time Frame: 3 years ]
Defined as the proportion of patients who have the best overall response a complete response, a partial response, or stable disease.
- Duration of Progression-Free Survival [ Time Frame: 3 years ]
Defined as the time elapsing between the start of treatment and the date of the earliest evidence of objective disease progression or death of any cause before documented disease-progression assessed through study completion.
|
- Intracranial Response Rate per blinded independent central review (RECIST 1.1) [ Time Frame: 3 years ]
defined as the proportion of patients achieving a best overall response of confirmed partial response + complete response, based on intracranial lesions (per RECIST version 1.1).
- Intracranial Response Rate per blinded independent central review (RANO) [ Time Frame: 3 years ]
defined as the proportion of patients achieving a best overall response of confirmed partial response plus complete response, based on intracranial lesions (per RANO criteria).
- Duration of Tumor Response [ Time Frame: 3 years ]
Measured as the time from the date of enrollment until the first date of documented disease progression or death due to any cause, whichever occurs first.
- Clinical Benefit Rate [ Time Frame: 3 years ]
Defined as the proportion of patients who have the best overall response a complete response, a partial response, or stable disease.
- Duration of Progression Free Survival [ Time Frame: 3 years ]
Defined as the time elapsing between the start of treatment and the date of the earliest evidence of objective disease progression or death of any cause before documented disease-progression assessed through study completion.
|
Not Provided
|
Not Provided
|
|
Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/HER2- Breast Cancer
|
An Open-label Multicenter Phase 1b-2 Study of Elacestrant in Combination With Abemaciclib in Women and Men With Brain Metastasis From Estrogen Receptor Positive, HER-2 Negative Breast Cancer
|
This is a multi-site, global, open-label study that includes a phase 1b evaluation of elacestrant in combination with abemaciclib in women and men with with or without brain metastases from ER-positive, HER-2 negative breast cancer. Phase 1b is designed to select the recommended phase 2 dose and will be followed by a phase 2 evaluation of elacestrant in combination with abemaciclib in patients with active brain metastases from ER-positive, HER-2 negative breast cancer.
|
Not Provided
|
Interventional
|
Phase 1 Phase 2
|
Allocation: Non-Randomized Intervention Model: Sequential Assignment Masking: None (Open Label) Primary Purpose: Treatment
|
- Breast Neoplasms
- Brain Neoplasms
- Neoplasms by Site
- Neoplasms
- Breast Diseases
- Central Nervous System Neoplasms
- Brain Diseases
- Central Nervous System Diseases
|
- Drug: Elacestrant
300 mg, 400 mg
Other Name: ELA-0121
- Drug: Abemaciclib
100 mg, 150 mg
Other Name: Verzenio
|
- Experimental: Phase 1b Cohort 1
Elacestrant 300 mg once daily (QD) + abemaciclib 100 mg twice daily (BID)
Interventions:
- Drug: Elacestrant
- Drug: Abemaciclib
- Experimental: Phase 1b Cohort 2
Elacestrant 400 mg QD + abemaciclib 100 mg BID
Interventions:
- Drug: Elacestrant
- Drug: Abemaciclib
- Experimental: Phase 1b Cohort 3
Elacestrant 400 mg QD + abemaciclib 150 mg BID
Interventions:
- Drug: Elacestrant
- Drug: Abemaciclib
- Experimental: Phase 2
Elacestrant in combination with abemaciclib at the recommended phase 2 dose (RP2D) determined in phase 1b
Interventions:
- Drug: Elacestrant
- Drug: Abemaciclib
|
Not Provided
|
|
Recruiting
|
106
|
Same as current
|
December 2025
|
December 2025 (Final data collection date for primary outcome measure)
|
Inclusion Criteria:
- Patient has the signed informed consent form before any study-related activities according to local guidelines.
-
Women or men aged ≥18 years, at the time of informed consent signature.
- Female patients may be either postmenopausal or premenopausal or perimenopausal. Postmenopausal status is defined by:
- Age ≥60 years
- Age <60 years and amenorrhea for 12 or more months (in the absence of chemotherapy, tamoxifen, toremifene, or ovarian suppression) or a follicle stimulating hormone (FSH) value >40 mIU/mL and an estradiol value <40 pg/mL (140 pmol/L) or in postmenopausal ranges per local reference ranges
- Documentation of prior bilateral oophorectomy, at least 1 month before first dose of trial therapy).
-
Patient must have ER-positive, HER-2 negative tumor status as confirmed by local laboratory testing either from a fresh biopsy or from an archival tissue obtained no more than 2 years prior to signing of the informed consent form.
- ER and HER-2 testing must be performed in the following manner:
- Documentation of ER positive tumor with ≥ 1% staining by immunohistochemistry (IHC) as defined in the 2010 or 2020 American Society for Clinical Oncology (ASCO) recommendations for ER testing, with or without progesterone receptor (PGR) positivity
- HER-2 negative tumor with an IHC result of 0 or 1+ for cellular membrane protein expression or an in situ hybridization negative result as defined in the 2013 or 2018 ASCO recommendations for HER-2 testing
- Patients receiving concomitant corticosteroids must be on a stable or decreasing dose for at least 7 days prior to baseline and not receiving doses higher than 4 mg of dexamethasone per day or equivalent.
- Any neurological symptoms of brain metastases must be stable for at least 2 weeks before starting trial therapy.
-
Patient has received prior therapy in the metastatic setting including:
- At least one endocrine therapy
- Up to two chemotherapy regimens
- Up to two prior CDK 4/6 inhibitors, not including abemaciclib
- If recurrence was observed while on adjuvant therapy or within 12 months of end of adjuvant therapy, this therapy will be counted as part of required prior therapy for eligibility.
- Toxicity from prior therapy must be resolved to National Cancer Institute (NCI) CTCAE version 5.0 Grade ≤1, with the exception of alopecia and peripheral sensory neuropathy (Grade ≤2).
- Patient has documented intra- and/or extra-cranial radiological progression or recurrence while on or after the most recent therapy.
- Patient has an Eastern Cooperative Oncology Group (ECOG) performance status of ≤2
-
Patient has adequate bone marrow and organ function, as defined by the following laboratory values:
- Absolute neutrophil count (ANC) ≥1.5 × 109/L
- Platelets ≥100 × 109/L
- Hemoglobin ≥9.0 g/dL
- Potassium, sodium, calcium (corrected for serum albumin) and magnesium CTCAE Grade ≤1 (if screening assessments are abnormal, these assessments may be repeated up to 2 times; subjects may receive appropriate supplementation or treatment prior to reassessment)
- Creatinine clearance (per Cockcroft-Gault formula) ≥50 mL/min
- Serum albumin ≥3.0 g/dL (≥30 g/L)
- In absence of liver metastases, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3.0 × ULN. If the patient has liver metastases, ALT and AST ≤5 × ULN
- Total serum bilirubin <1.5 × ULN except for patients with Gilbert's syndrome who may be included if the total serum bilirubin is ≤3.0 × ULN or direct bilirubin ≤ 1.5 × ULN
- The patient is able and willing to adhere to the study visit schedule and other protocol requirements.
-
For Phase 1b, the presence of brain metastases is allowed but not required for eligibility. In Phase 2, patients must have at least one active and measurable brain metastasis per RECIST version 1.1
Exclusion Criteria:
- Immediate CNS-specific treatment is likely to be required, per the treating physician's assessment.
- Patient has imminent organ failure and/or visceral crisis.
- Patient has leptomeningeal metastases, defined as having positive CSF cytology or unequivocal radiologic or clinical evidence of leptomeningeal involvement.
- Breast cancer treatment-naïve patients in the metastatic setting. Patients who experience a recurrence while on adjuvant therapy or within 12 months of end of adjuvant therapy are allowed.
- Prior therapy with abemaciclib in the metastatic setting. Note: Use of abemaciclib in the adjuvant setting is allowed if the last treatment administration was more than 12 months prior to first recurrence.
- Prior therapy with elacestrant or other investigational SERDs, or alike agents such as SERMs, SERCANs, CERANs, and PROTACs in the metastatic setting.
- Patient has a concurrent malignancy or malignancy within 3 years of enrollment, with the exception of adequately treated basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix, or second primary breast cancer.
- Currently participating in another breast cancer intervention clinical study. Patients who are being followed for overall survival for another clinical trial with no therapy and study intervention are allowed after the washout period for any prior therapy.
-
Prior anti-cancer or investigational drug treatment within the following windows:
- Fulvestrant treatment (last injection) <42 days before first dose of study drug
- Any other endocrine therapy <14 days or <5 half-lives, whichever is shorter, before first dose of study drug
- Chemotherapy or other anti-cancer therapy <21 days before first dose of study drug
- Any investigational anti-cancer drug therapy within <28 days or <5 half lives, whichever is shorter
- Bisphosphonates or RANKL inhibitors initiated, or dose changed <1 month prior to first dose of study drug.
- Radiation therapy (other than CNS directed) within 14 days before the first dose of study drug.
-
Uncontrolled significant active infections
- Patients with hepatitis B virus (HBV) and/or hepatitis C virus (HCV) infection must have undetectable viral load during screening
- Patients known to be HIV+ are allowed as long as they have undetectable viral load at baseline.
- Major surgery within 4 weeks of starting trial therapy.
- Inability to take oral medication, or history of malabsorption syndrome or any other uncontrolled gastrointestinal condition.
-
Females of childbearing potential who do not agree to use a highly effective non-hormonal method of contraception throughout within 28 days of the first dose of study treatment until 28 days of the last dose of study treatment. Highly effective non-hormonal method of contraception includes any of the following:
- Intrauterine device (non-hormonal)
- Total abstinence
- Bilateral tubal occlusion/ligation
- Have a vasectomized partner with confirmed azoospermia.
- Men who do not agree abstain from donating sperm or to use a highly effective barrier contraception (use condoms) during the treatment period and for 120 days thereafter. For subjects (who have not undergone vasectomy) with female partners of childbearing potential, the subject and his partner must, in addition to condoms, use highly effective methods of contraception.
- Females who are breastfeeding or pregnant.
- Known intolerance to either study drug or any of the excipients.
-
Patients currently receiving or received any of the following medications prior to first dose of trial therapy:
- Known strong or moderate inducers or inhibitors of cytochrome P450 (CYP) 3A4 within 21 days prior to initiating trial therapy
- Herbal preparations/medications These include, but are not limited to, St. John's wort, kava, ephedra (ma huang), gingko biloba, dehydroepiandrosterone (DHEA), yohimbe, saw palmetto, and ginseng within 21 days prior to initiating trial therapy
- Vaccination, including but not limited to vaccination against COVID-19, during the 7 days prior to randomization.
- Any severe medical or psychiatric condition that in the opinion of the investigator(s) would preclude the patient's participation in a clinical study.
|
Sexes Eligible for Study: |
All |
|
18 Years and older (Adult, Older Adult)
|
No
|
|
Belgium, France, Germany, Greece, Italy, Korea, Republic of, Spain, United Kingdom, United States
|
|
|
NCT05386108
|
ELA-0121
|
Yes
|
Studies a U.S. FDA-regulated Drug Product: |
Yes |
Studies a U.S. FDA-regulated Device Product: |
No |
|
|
Stemline Therapeutics, Inc.
|
Same as current
|
Stemline Therapeutics, Inc.
|
Same as current
|
Not Provided
|
Not Provided
|
Stemline Therapeutics, Inc.
|
April 2024
|